Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 1/2008

01-03-2008 | Original Paper

BMI-1 Expression is Inversely Correlated with the Grading of Renal Clear Cell Carcinoma

Authors: Nicolas Kozakowski, Afschin Soleiman, Johannes Pammer

Published in: Pathology & Oncology Research | Issue 1/2008

Login to get access

Abstract

BMI-1 regulates cell proliferation and differentiation, is involved in stem cell maintenance and can act as an oncogene. We investigated BMI-1 expression in healthy normal kidney and in 77 renal tumours by immunohistochemistry, and correlated it with tumour differentiation. BMI-1 could regularly be demonstrated in distal tubules and in Bowman’s capsule, whereas it was mostly lacking in proximal tubules, indicating that it may rather be a differentiation marker of different renal cell populations than a stem cell marker. In contrast to previous studies demonstrating a correlation between BMI-1 expression and malignancy, we showed that its expression was inversely correlated with the differentiation grade of clear cell carcinoma. Furthermore, despite their different biologies, BMI-1 was strongly expressed in both papillary carcinomas and oncocytomas. Thus, in renal clear cell carcinomas BMI-1 is rather a differentiation marker lost in carcinomas with high malignancy than an oncogene involved in tumour progression.
Literature
1.
Jacobs JJ, Kieboom K, Marino S et al (1999) The oncogene and Polycomb-group gene BMI-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397:164–168PubMedCrossRef
2.
Jacobs JJ, Scheijen B, Voncken JW et al (1999) BMI-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev 13:2678–2690PubMedCrossRef
3.
Kim JH, Yoon S, Kim CN et al (2004) The BMI-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 203:217–224PubMedCrossRef
4.
Liu S, Dontu G, Mantle ID et al (2006) Hedgehog signaling and BMI-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66:6063–6071PubMedCrossRef
5.
Raaphorst F (2003) Self-renewal of hematopoietic and leukemic stem cells: a central role for the Polycomb-group gene BMI-1. Trends Immunol 24:522–524PubMedCrossRef
6.
Muller J, Gaunt S, Lawrence PA (1995) Function of the Polycomb protein is conserved in mice and flies. Development 121:2847–2852PubMed
7.
Lessard J, Schumacher A, Thorsteinsdottir U et al (1999) Functional antagonism of the Polycomb-Group genes eed and BMI1 in hemopoietic cell proliferation. Genes Dev 13:2691–2703PubMedCrossRef
8.
Van Kemenade FJ, Raaphorst FM, Blokzijl T et al (2001) Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 7:3896–3901CrossRef
9.
Leung C, Lingbeek M, Shakhova O et al (2004) BMI1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 428:337–341PubMedCrossRef
10.
Pirrotta V (1997) PcG complexes and chromatin silencing. Curr Opin Genet Dev 2:249–258CrossRef
11.
Saurin AJ, Shiels C, Williamson J et al (1998) The human Polycomb group complex associates with pericentromeric heterochromatin to form a novel nuclear domain. J Cell Biol 142:887–898PubMedCrossRef
12.
Bea S, Tort F, Pinyol M et al (2001) BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 61:2409–2412PubMed
13.
Kim JH, Yoon S, Jeong SH et al (2004) Overexpression of BMI-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 13:383–388PubMedCrossRef
14.
Breuer RH, Snijders P, Sutedja GT et al (2005) Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer 48(3):299–306PubMedCrossRef
15.
Van Leenders GJ, Dukers D, Hessels D et al (2007) Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 52(2):455–63PubMedCrossRef
16.
Van Galen JC, Muris J, Oudejans JJ et al (2007) Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL. J Clin Pathol 60:167–172PubMedCrossRef
17.
18.
Martel CL, Lara PN (2003) Renal cell carcinoma: current status and future directions. Crit Rev Oncol Hematol 45:177–190PubMedCrossRef
19.
Reya T, Morrison S, Clarke MF et al (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105–111PubMedCrossRef
20.
Valk-Lingbeek ME, Bruggeman S, Van Lohuizen M (2004) Stem cells and cancer: the Polycomb connection. Cell 118:409–418PubMedCrossRef
21.
22.
Oliver JA, Maarouf O, Cheema FH et al (2004) The renal papilla is a niche for adult kidney stem cells. J Clin Invest 114:795–804PubMed
23.
Gupta S, Verfaillie C, Chmielewski D et al (2006) Isolation and characterization of kidney-derived stem cells. J Am Soc Nephrol 17(11):3028–40PubMedCrossRef
24.
Fuhrman SA, Lasky L, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655–663PubMedCrossRef
25.
Sika-Paotonu D, Bethwaite P, McCredie MRE et al (2006) Nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma. Am J Surg Pathol 30:1091–1096PubMed
26.
Delahunt B, Sika-Paotonu D, Bethwaite PB et al (2007) Fuhrman grading is not appropriate for chromophobe renal cell carcinoma. Am J Surg Pathol 31:957–960PubMedCrossRef
27.
Lessard J, Sauvageau G (2003) BMI-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423:255–260PubMedCrossRef
28.
29.
Sanchez-Beato M, Sanchez E, Gonzalez-Carrero J et al (2006) Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays. Mod Pathol 19:684–694PubMedCrossRef
30.
Bussolati B, Bruno S, Grange C et al (2005) Isolation of renal progenitor cells from adult human kidney. Am J Pathol 166:545–555PubMed
31.
Sagrinati C, Netti G, Mazzinghi B et al (2006) Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. J Am Soc Nephrol 17:2443–2456PubMedCrossRef
Metadata
Title
BMI-1 Expression is Inversely Correlated with the Grading of Renal Clear Cell Carcinoma
Authors
Nicolas Kozakowski
Afschin Soleiman
Johannes Pammer
Publication date
01-03-2008
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 1/2008
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-008-9006-3

Other articles of this Issue 1/2008

Pathology & Oncology Research 1/2008 Go to the issue

Original Paper

Oral Cancer Report from Northeastern Hungary

Original Paper

A Prenatally Detected Case of Congenital Hepatoblastoma

Original Paper

p53 and BCL-2 as Prognostic Markers in Endometrial Carcinoma

Original Paper

Matrix Metalloproteinase-9 Expression in the Normal Mucosa–Adenoma–Dysplasia–Adenocarcinoma Sequence of the Colon

Original Paper

Early Diagnosis of Chemotherapy-induced Cardiomyopathy: a Prospective Tissue Doppler Imaging Study

Original Paper

Somatic APC Inactivation Mechanisms in Sporadic Colorectal Cancer Cases in Hungary
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits